TPTimothy Pham

Timothy Pham

*This is an algorithmically generated author record based on publicly available information.

Timothy Pham has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors

    by Ying Liu, Samyukta Mullangi, David Debono, Xiaoxue Chen, Timothy Pham, Michael J. Fisch, Aliza S. Gordon, Dawn L. Hershman

    PURPOSE This retrospective observational study compared cancer care toxicity and cost outcomes for patients with metastatic cancer with nine different cancer types prescribed on- versus off-pathway regimens.METHODS This study used claims and authorization data from a national insurer between January 1, 2018, and October 31, 2021. Participants included adults with metastatic breast, lung, colorectal, pancreatic, melanoma, kidney, bladder, gastric, or uterine cancer, who were prescribed first-line anticancer regimens. Multivariable regressions were used to assess outcomes including counts of emergency room visits or hospitalizations, use of supportive care medications, immune-related adverse events (IRAEs), and health care costs.RESULTS Of the 8,357 patients in the study, 5,453 (65.3%) were prescribed on-pathway regimens. The on-pathway proportion trended downward, from 74.3% in 2018 to 59.8% in 2021. The on- and off-pathway groups had a similar proportion of patients with treatment-related hospitalization (adjusted odds ratio [aOR], 1.080; P = .201) and IRAEs (aOR, 0.961; P = .497). More all-cause hospitalizations (aOR, 1.679; P = .013) were observed among patients with melanoma treated on-pathway. The on-pathway group had higher use of supportive care drugs in bladder cancer (aOR, 4.602; P < .001) and colorectal cancer (aOR, 4.465; P < .001), and lower use in breast (aOR, 0.668; P = .001) and lung cancer (aOR, 0.550; P < .001). On average, on-pathway patients incurred $17,589 less total health care cost (P < .001), and $22,543 lower chemotherapy cost (P < .001) than those from the off-pathway group.CONCLUSION Our findings suggest that use of on-pathway regimens was associated with significant cost savings. Toxicity outcomes were variable by disease, but overall, there were similar numbers of treatment-related hospitalizations and IRAEs compared to off-pathway regimens. This cross-institutional study provides evidence to support the use of clinical pathway regimens for patients with metastatic cancer.


  • Predictors of compliance with payer-led oncology clinical pathways.

    by Samyukta Mullangi, Xiaoxue Chen, Timothy Pham, Ying Liu, Aliza Gordon, David Joseph Debono, Michael Jordan Fisch, Mithat Gonen, Dawn L. Hershman

    7 Background: Rising healthcare costs have garnered interest from payers in shifting oncology care towards a value-based practice model. Pathways are a subset of evidence-based guidelines designed to standardize cancer drug prescribing by clarifying decisions along three priorities: efficacy, safety, and cost. However, the major predictors of compliance with clinical pathway recommendations are unknown. Methods: We conducted a retrospective cohort study using administrative claims linked with prior authorization data of Anthem commercial and Medicare Advantage members. We identified members aged 18 or older with a diagnosis of breast, lung, colorectal, bladder, kidney, uterine, pancreatic cancer or melanoma being treated with a first-line treatment regimen in the metastatic setting between July 2018 and October 2021. The primary outcome was pathway compliance (PC), defined as whether a patient’s anti-cancer drug regimen is also an Anthem pathway-endorsed regimen. We built a logistic regression model with stepwise backward selection to identify patient, physician, practice, geographic, and temporal factors that were associated with PC. Results: The cohort comprised 17,584 patients in total. The treatment period yielded 11,277 (64%) observations of patients with PC (48.1% male, mean [SD] age 60.7 years [11]) and 6,307 (36%) without PC (45.1% male, mean [SD] age 60.4 years [11.6]). In adjusted analyses, we find that the odds of PC decrease over time and with variation by malignancy. Any inpatient (OR = 1.32, 95% CI 1.22 – 1.43) or emergency room utilization (OR = 1.21, 95% CI 1.12 – 1.31) in the baseline 6-month period was associated with a higher odds of PC. Conversely, doubling total medical costs in the preceding 6 months was associated with lower odds of PC (OR 0.86, 95% CI 0.83 – 0.88). The odds of PC increased with a higher share (median or above vs below median) of Anthem patients per physician (OR 1.12, 95% CI 1.04 – 1.20). Finally, Oncology Care Model participation was associated with higher odds of PC (OR = 1.13 95% CI 1.04 – 1.23). Conclusions: Among patients treated in the first-line setting for metastatic disease, PC was observed in slightly under two-thirds of cases and was associated with the penetration of Anthem patients in the practice. Participation in OCM was also associated with increased PC. These findings would be of interest to policymakers focused on value-based cancer care.

  • Treatment patterns, clinical outcomes, and costs following the approval of new systemic therapy medications for hepatocellular carcinoma.

    by Timothy Pham, Aliza Gordon, David Joseph Debono, Michael Jordan Fisch

    398 Background: Between March 2017 and May 2020, ten new systemic medication therapies for hepatocellular carcinoma (HCC) were approved for the US market. However, clinical trials for medications only showed marginal improvement in health outcomes compared to placebo or sorafenib, the only medication previously approved for HCC. The objective of this study was to examine the change in treatment patterns and outcomes of incident patients with HCC before and after multiple medication approvals. Methods: This observational cohort study used administrative medical and pharmacy claims data for adult commercially insured and Medicare Advantage patients with at least two diagnoses of HCC during July 2013 to December 2020. Patients were categorized into two groups: the pre-approval group (identified between July 2013 and March 2017) and the post-approval group (identified between April 2017 and December 2020). We compared systemic therapy treatment (e.g., sorafenib and lenvatinib) patterns, survival, hospitalization for serious infections, other treatments such as G-CSF use and liver transplants, and cost (e.g, total all-cause costs and anti-HCC systemic therapy). Generalized linear model and Cox proportional hazards regression were used to assess the effect of new approvals on outcomes while controlling for baseline characteristics. Results: We identified 2,730 patients in the pre-approval group and 2,290 patients in the post-approval group. After risk adjustment, the latter was more likely to use systemic therapy medications (20.4% vs. 13.7%, adjusted odds ratio [aOR] 1.41, 95% confidence interval [CI] 1.22-1.62). Overall survival remained similar between the two groups (adjusted hazard ratio [HR] 0.96, 95% CI 0.87-1.06) and among the subsets who used systemic therapy (aHR 1.10, 95% CI 0.91-1.32). Odds of liver transplant (aOR 1.03, 95% CI 0.80-1.34) and hospitalization for serious infections (aOR 0.95, 95% CI 0.87-1.09) were similar, while the post-approval group had lower odds of G-CSF use (aOR 0.59, 95% CI 0.48-0.73). No differences in total per-member-per-month (PMPM) costs were seen, but the post-approval group had lower PMPM pharmacy-related costs (adj cost diff -$1,188, 95% CI -$1,575 to -$755) and higher PMPM systemic therapy costs (adj cost diff $971, 95% CI $584 to $1446). Conclusions: As expected, use of newer systemic therapies in HCC patients increased following approval of new medications. However, there was no associated change in clinical outcomes such as survival or serious infections, providing additional real-world evidence of marginal improvement, if any. Pharmacy costs decreased in the post-approval group, which may reflect a shift from oral sorafenib to newer injectable systemic therapies.

  • Association between oncology clinical pathway utilization and quality and cost outcomes in patients with metastatic solid tumors.

    by Ying Liu, Samyukta Mullangi, Xiaoxue Chen, Timothy Pham, David Joseph Debono, Michael Jordan Fisch, Aliza Gordon, Dawn L. Hershman

    430 Background: Anticancer drug regimens that are approved by accepted drug compendia and also considered high value based on their efficacy, toxicity, and costs are designated as “on-pathway” for a national commercial payer. This study compared quality and cost of cancer care among patients with metastatic solid tumors treated in the first line setting who were prescribed on- vs. off-pathway regimens. Methods: Using administrative claims data and prior authorization data from a national commercial payer, we identified 8,357 commercially insured or Medicare Advantage adult patients with solid tumor cancers including breast, lung, colorectal, pancreatic, melanoma, kidney, bladder, gastric, or uterine cancer, who were prescribed first-line anti-cancer regimens in the metastatic setting from 2018 to 2021. Patients were classified into on- vs. off pathway group based on the initial anticancer regimen that was prescribed. On-pathway status was prospectively defined by a panel of practicing oncologists based on review of curated evidence and general application of relative clinical value frameworks accepted in the field. We compared post–6-month quality-of-care outcomes including chemotherapy-related avoidable hospitalizations, emergency room (ER) visits, immune-related adverse events (IRAEs) such as endocrinopathies owing to immune checkpoint inhibitors, need for supportive drugs such as granulocyte colony stimulating factor, and cost outcomes between groups. Generalized linear models were used to assess the association between on-pathway regimens and outcomes adjusting for key patient demographics, clinical and provider characteristics. Results: A total of 5,453 (65.3%) patients were prescribed on-pathway regimens. Both groups had similar age (60.1 vs. 59.6, p = 0.06) and ECOG performance status (0.63 vs. 0.62, p = 0.40), with more females in the off-pathway group (54.6% vs. 57.3%, p = 0.02). There was no statistically significant difference in chemotherapy-related avoidable hospitalizations, IRAEs and need for supportive drugs between the two groups after modeling adjustment. However, patients treated on-pathway had higher rates of chemotherapy-related avoidable ER visits (18% vs. 15%, adjusted odds ratio: 1.16, 95% confidence interval (CI): 1.01 to 1.33, p = 0.03). Patients in the on-pathway group had significantly lower 6-month anticancer treatment cost (adjusted cost difference: -$10410, 95% CI: -$14935 to -$5886, p < 0.01), resulting in an overall lower total healthcare costs (adjusted cost difference: -$12826, 95% CI: -$18879 to -$6773, p < 0.01). Conclusions: Pathway regimens for metastatic solid tumors were associated with reduced total healthcare costs and similar quality of care compared with off-pathway regimens. These findings support the use of high value, evidence-based regimens for metastatic cancer patients.

  • Effectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management

    by Timothy T. Pham, Xiaoxue Chen, John Barron, Richard Hart, Jacob Abarca, Andrea DeVries

    Aim: To assess the change in HbA1c after initiation of biosimilar follow‐on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2 diabetes. We also compared treatment adherence, safety events and costs at 1 year after initiation of insulin. Materials and Methods: Using claims data from a large US health plan during 2016‐2020, we identified adults with type 2 diabetes who initiated either Basaglar or Lantus. Generalized linear regression modelling assessed the differences in outcomes between the two groups. A 0.4% margin was used to determine non‐inferiority for HbA1c. Results: The study included 1136 Basaglar users and 6304 Lantus users. Both Lantus and Basaglar groups showed more than 1% reduction in HbA1c over 6 months and over 12 months. Reduction in HbA1c with Basaglar was similar (non‐inferior) to that with Lantus, with an adjusted difference of Basaglar to Lantus of 0.14% (95% CI −0.02 to 0.30) over 6 months and 0.17% (95% CI 0.02 to 0.32) over 12 months. Rates of adverse events were similar for both hypoglycaemia and vascular events. The Basaglar group showed higher adherence in terms of proportion of days covered (adjusted difference 0.06, 95% CI 0.04 to 0.08). Medical costs were similar, but the cost of Basaglar was lower (adjusted mean cost difference −$462, 95% CI −$556 to −$363) after adjustment. Conclusions: In patients with type 2 diabetes, Basaglar provided similar glycaemic control compared with Lantus, had a similar safety profile and lower drug costs, and showed more favourable adherence.


  • Open Access

    Cross-Sectional Trends in Potentially Low-Value Services for Commercially Insured Patients With Chronic Low Back Pain

    by Timothy Pham, Andrea DeVries, Eric Bailly, Dheeraj Raina

    Neck pain and low back pain (LBP) account for the third-highest category of health care spending in the US, after diabetes and ischemic heart disease.1 Many treatments for LBP are ineffective and potentially harmful. The International Association for the Study of Pain considers overuse of diagnostic imaging, opioids, spinal injections, and surgery to be of low value.2 Despite published guidelines, practice patterns have been slow to change. For example, a 2015 analysis3 found that the use of imaging and other potentially low-value services for LBP remained high after release of the Choosing Wisely recommendations. This cross-sectional study characterizes trends in services for commercially insured patients with LBP over a 9-year period.


  • Open Access

    Do Acupuncture Services Reduce Subsequent Utilization of Opioids and Surgical Interventions Compared to Noninvasive Therapies among Patients with Pain Conditions?

    by Timothy Pham, Qinli Ma, Abiy Agiro, Julie Bukowiec, Terry Flannery

    To compare prescribed opioid use and invasive surgical interventions between patients using acupuncture and those using non-steroidal anti-inflammatory drugs (NSAIDs)/physical therapy (PT). Retrospective observational study of administrative claims. Large commercial insurance plan. 52 346 each treated with either acupuncture or NSAIDs/PT. Users of acupuncture and NSAIDs/PT were identified from January 1, 2014, to December 31, 2017. The first date of each service was defined as the index date. Acupuncture patients were 1:1 propensity score matched to the NSAIDs/PT group on baseline characteristics. Outcomes included opioid use, subsequent invasive surgical procedures, healthcare utilization such as hospitalizations or emergency department (ED) visits, and costs. These were assessed in the 12-month period before index date (baseline) and 12-month period following index date (follow-up) using difference-in-difference (DID) analysis. Results for opioid use were stratified by those with and without baseline opioid use. The acupuncture group had fewer patients initiating opioids post-index both among those with (49.2% vs 56.5%, P < .001) and without (15.9% vs 22.6%, P < .001) baseline opioid use. There was a small increase in invasive surgical procedures with acupuncture (3.1% vs 2.8%, P = .006). A reduction in ED visits was observed with acupuncture (DID −4.6% for all-cause; −3.3% for pain-related, all P < .001). Acupuncture was associated with higher total medical and pharmacy costs (DID +$1331 per patient, P = .006). Acupuncture showed a modest effect in reducing opioid use and ED visits. More research on acupuncture’s place in emergency care, pain relief, and comparison to other types of non-opioid treatment is needed.


  • National estimates of case‐mix, mortality, and economic outcomes among inpatient HIV/AIDS mono‐infection and hepatitis C co‐infection cases in the US

    by Timothy Pham, R. Chris Rathbun, Shellie Keast, Nancy Nesser, Kevin Farmer, Grant Skrepnek

    Rationale, aims, and objectives: To assess inpatient clinical and economic outcomes for AIDS/HIV and Hepatitis C (HCV) co‐infection in the United States from 2003 to 2014. Method: This historical cohort study utilized nationally representative hospital discharge data to investigate inpatient mortality, length of stay (LoS), and inflation‐adjusted charges among adults (≥18 years). Outcomes were analysed via multivariable generalized linear models according to demographics, hospital and clinical characteristics, and AIDS/HIV or HCV sequelae. Results: Overall, 17.8% of the 2.75 million estimated AIDS/HIV inpatient cases involved HCV from 2003 to 2014, averaging 48.5 ± 9.0 years of age and 68.0% being male. Advanced sequalae of AIDS and HCV incurred a LoS of 10.3 ± 11.9 days, charges of $88 789 ± 131 787, and a 16.9% mortality. Many cases involved noncompliance, tobacco use disorders, and substance abuse. Although mortality decreased over time, multivariable analyses indicated that poorer outcomes were generally associated with more advanced clinical conditions and AIDS‐associated sequalae, although mixed results were observed for specific manifestations of HCV. Rural residence was independently associated with a 3.26 times higher adjusted odds of mortality from 2009 to 2014 for HIV/HCV co‐infection ( P < 0.001), although not for AIDS/HCV (OR = 1.38, P = 0.166). Conclusion: Given the systemic nature and modifiable risks inherent within coinfection, more proactive screening and intervention appear warranted, particularly within rural areas.